CN100528177C - Red yeast preparation containing active components of glossy ganoderma and its preparation process - Google Patents
Red yeast preparation containing active components of glossy ganoderma and its preparation process Download PDFInfo
- Publication number
- CN100528177C CN100528177C CNB2004100790919A CN200410079091A CN100528177C CN 100528177 C CN100528177 C CN 100528177C CN B2004100790919 A CNB2004100790919 A CN B2004100790919A CN 200410079091 A CN200410079091 A CN 200410079091A CN 100528177 C CN100528177 C CN 100528177C
- Authority
- CN
- China
- Prior art keywords
- preparation
- powder
- lovastatin
- monas cuspurpureus
- cuspurpureus went
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940057059 monascus purpureus Drugs 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 241000222336 Ganoderma Species 0.000 title claims description 59
- 238000000855 fermentation Methods 0.000 claims abstract description 42
- 230000004151 fermentation Effects 0.000 claims abstract description 42
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims abstract description 41
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims abstract description 41
- 229960004844 lovastatin Drugs 0.000 claims abstract description 41
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims abstract description 41
- 150000004676 glycans Chemical class 0.000 claims abstract description 39
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 39
- 239000005017 polysaccharide Substances 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 239000002775 capsule Substances 0.000 claims abstract description 13
- 239000002778 food additive Substances 0.000 claims abstract description 9
- 235000013373 food additive Nutrition 0.000 claims abstract description 8
- 239000002674 ointment Substances 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 8
- 244000113306 Monascus purpureus Species 0.000 claims description 56
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 56
- 229930003944 flavone Natural products 0.000 claims description 37
- 235000011949 flavones Nutrition 0.000 claims description 37
- 150000002213 flavones Chemical class 0.000 claims description 36
- 239000000047 product Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000012265 solid product Substances 0.000 claims description 19
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 18
- 230000001954 sterilising effect Effects 0.000 claims description 17
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 238000012856 packing Methods 0.000 claims description 10
- 239000007901 soft capsule Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 8
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 8
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 7
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 7
- 239000004137 magnesium phosphate Substances 0.000 claims description 7
- 229960002261 magnesium phosphate Drugs 0.000 claims description 7
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 7
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 7
- 235000010344 sodium nitrate Nutrition 0.000 claims description 7
- 239000004317 sodium nitrate Substances 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 5
- 229960004998 acesulfame potassium Drugs 0.000 claims description 5
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 5
- 239000000619 acesulfame-K Substances 0.000 claims description 5
- 238000004040 coloring Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012263 liquid product Substances 0.000 claims description 3
- 201000002909 Aspergillosis Diseases 0.000 claims description 2
- 208000036641 Aspergillus infections Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004185 liver Anatomy 0.000 abstract description 5
- 239000013543 active substance Substances 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 3
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract description 2
- 239000011573 trace mineral Substances 0.000 abstract description 2
- 240000008397 Ganoderma lucidum Species 0.000 abstract 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract 6
- 229940026314 red yeast rice Drugs 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 3
- 229930003935 flavonoid Natural products 0.000 abstract 2
- 150000002215 flavonoids Chemical class 0.000 abstract 2
- 235000017173 flavonoids Nutrition 0.000 abstract 2
- 235000014214 soft drink Nutrition 0.000 abstract 1
- 239000000306 component Substances 0.000 description 36
- 230000006870 function Effects 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 244000152526 Agathosma crenulata Species 0.000 description 1
- 235000013388 Agathosma crenulata Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 235000009269 Barosma crenulata Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000038561 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- 241001095209 Monascus sp. (in: Fungi) Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940062650 buchu Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种含有灵芝活性成分的红曲制剂及其制备方法。本发明是由含有灵芝活性成分的红曲发酵物制成，其主要功效成份粗多糖≥4mg/100g、总黄酮≥3mg/100g、洛伐他汀≥0.1mg/100g；能制成口服液、软胶囊剂、粉(散)剂、胶囊剂、片剂、蜜丸剂、膏剂、食品添加剂等剂型。本发明利用现代生物技术制成的含有灵芝活性成分的红曲制剂，工艺先进，简单可行，不但具有灵芝、红曲发酵产物的多种生理活性物质，富含有大量多糖、黄酮、洛伐他汀、不饱和脂肪酸、蛋白质、氨基酸、r-氨基丁酸、微量元素等。本发明兼具红曲的降血脂功能及灵芝的保肝护肝功能，且功效较单一的灵芝和红曲更佳。The invention provides a red yeast rice preparation containing ganoderma lucidum active ingredients and a preparation method thereof. The invention is made from red yeast fermented product containing ganoderma lucidum active ingredients, its main functional components are crude polysaccharide≥4mg/100g, total flavonoid≥3mg/100g, lovastatin≥0.1mg/100g; it can be made into oral liquid, soft drink Capsules, powder (powder), capsules, tablets, honeyed pills, ointments, food additives and other dosage forms. The red yeast rice preparation containing the active ingredients of Ganoderma lucidum produced by modern biotechnology has advanced technology, is simple and feasible, not only has various physiologically active substances of fermentation products of Ganoderma lucidum and red yeast rice, but also contains a large amount of polysaccharides, flavonoids, and lovastatin , unsaturated fatty acids, proteins, amino acids, r-aminobutyric acid, trace elements, etc. The invention has both the function of reducing blood fat of red yeast rice and the function of protecting the liver of ganoderma lucidum, and has better efficacy than single ganoderma lucidum and red yeast rice.
Description
Technical field
The invention belongs to the improvement of health food component, relate in particular to the liquid fermentation technology field.
Background technology
Monas cuspurpureus Went is the song that the fungus monascus (Monascus sp. comprises monascus and Mauve aspergillar) that utilizes occurring in nature to exist is produced, because of it be a peony, and the generation red pigments, so promptly be referred to as Monas cuspurpureus Went since ancient times.Monas cuspurpureus Went is used to pigment, food fermentation and drinks traditionally and brewages at the applicating history of the existing more than one thousand years of China, is widely used in the fields such as beverage, food, cosmetics.According to the Compendium of Material Medica record, Monas cuspurpureus Went has the function of " help digestion and invigorate blood circulation, the dry stomach of spleen invigorating ".Recent studies finds that Monas cuspurpureus Went has many drug effects: blood lipid regulation, and blood sugar lowering, antibiotic, anti-cancer, enhancing immunity, anti-inflammatory and antioxidation, hypotensive activity reduces senile dementia etc.The prevalence of China's hyperlipidemia is up to more than 7%, and is the trend that increases year by year.At present, the control of hyperlipidemia mainly based on Western medicine, is also brought serious toxic and side effects, as blood fat disorder, hepatic and renal function damage etc. in the time of blood fat reducing.There is a big chunk people to resist medication among the higher crowd of blood fat, makes hyperlipidemia can not get control, finally cause the generation of tragedy because of fearing the toxic and side effects that produces of taking medicine.In recent years, China develops the blood fat reducing medicine that some are raw material with the Monas cuspurpureus Went, and as " zhibituo " medicine of Chengdu buchu, main component is the Monas cuspurpureus Went powder that Monas cuspurpureus Went strain rice solid fermentation obtains.The function of present domestic Monas cuspurpureus Went class health product mostly is the Monas cuspurpureus Went powder that adopts the strains solid fermented production of Monas cuspurpureus Went to obtain based on blood fat reducing, as: " the Monas cuspurpureus Went tablets of reducing blood fat " of " Dongfanghong knee-piece ", Beijing University dimension letter, red Buddhist woods capsule etc.The liquid preparation that minority has Monas cuspurpureus Went fermentation liquid or blends with other compositions, as: the monascus healthy wine on Yun Xi farm, the military region, Jiangsu Province etc.Monas cuspurpureus Went can be taken for a long time as the blood lipid regulation health food, and the higher people of most blood fat can be well controlled.
Both at home and abroad Monas cuspurpureus Went adopts solid fermentation production more, has many shortcomings, as the production cycle is long, the productive labor amount is big, production scale is difficult for enlarging, the bioactive substance separation and Extraction is difficult and be difficult for measuring etc.
Ganoderma is Chinese Traditional health care food, just is considered to lucky, rich and honour, fine, life-prolonging symbol since ancient times, and the title of " Herba mesonae chinensis ", " Ganoderma " is arranged, and chinese tradition medical science is regarded it as strengthening by means of tonics for a long time always, consolidated the precious Chinese herbal medicine of setting upright.The folklore Ganoderma have come back to life, effect alive for evermore.In the Shennong's Herbal Ganoderma is classified as top gradely, think " food for a long time, it is not old to make light of one's life by commiting suicide, the angle prolongs life ".Put down in writing in the Compendium of Material Medica: Ganoderma bitter in the mouth, flat, nontoxic, the beneficial motive is invigorated blood circulation, and goes into heart hyperemia, helps the heart to fill arteries and veins, calm the nerves, lung benefiting gas, tonifying liver gas, invigorating middle warmer increases wisdom, good color, sharp joint, hard muscles and bones is eliminated the phlegm, and is good for the stomach.Modern medicine proves: Ganoderma contains several physiological active substances, has better protect liver, enhance immunity, radioprotective, anoxia enduring, the anti-ageing effect of waiting for a long time.
China is that the health food product of main component is numerous with the Ganoderma, mostly is the extraction method preparation, and for example: Chinese ganoderma extract, " middle section " Ganoderma spore oil, sporoderm-broken Ganoderma spore electuary, Ganoderma tea, LINGZHI JIAONANG etc., function is mainly immunomodulating, defying age.
Summary of the invention
The purpose of this invention is to provide monascus preparation that contains active components of glossy ganoderma and preparation method thereof, make its product have the hepatoprotective function of Ganoderma and the hypolipemic function of Monas cuspurpureus Went, and the more single Ganoderma of effect or monascus product are more remarkable; And make preparation method have the technology simple possible, and all raw materials can be fully used, obtain the several formulations product, satisfy the requirement of product quality simultaneously.
The characteristics that contain the monascus preparation of active components of glossy ganoderma provided by the invention are, said preparation is to be made by the red koji fermentation thing that contains active components of glossy ganoderma, its main effective component crude polysaccharides 〉=4mg/100g, total flavones 〉=3mg/100g, lovastatin 〉=0.1mg/100g; Can make following any dosage form: oral liquid, soft capsule, powder (loosing) agent, capsule, tablet, honey pill agent, unguentum, food additive.
Main effective component content is in the various dosage form of the present invention:
Oral liquid: crude polysaccharides 〉=5mg/100g, total flavones 〉=4mg/100g, lovastatin 〉=0.15mg/100g; Soft capsule: crude polysaccharides 〉=9mg/100g, total flavones 〉=7mg/100g, lovastatin 〉=0.25mg/100g; Powder (loosing) agent: crude polysaccharides 〉=8mg/100g, total flavones 〉=6mg/100g, lovastatin 〉=0.2mg/100g; Capsule: crude polysaccharides 〉=8mg/100g, total flavones 〉=6mg/100g, lovastatin 〉=0.2mg/100g; Tablet: crude polysaccharides 〉=7mg/100g, total flavones 〉=5mg/100g, lovastatin 〉=0.15mg/100g; Honey pill agent: crude polysaccharides 〉=5mg/100g, total flavones 〉=4mg/100g, lovastatin 〉=0.13mg/100g; Unguentum: crude polysaccharides 〉=4mg/100g, total flavones 〉=3mg/100g, lovastatin 〉=0.1mg/100g; Food additive: crude polysaccharides 〉=4mg/100g, total flavones 〉=3mg/100g, lovastatin 〉=0.1mg/100g.
Two kinds of preparation methoies that contain the monascus preparation of active components of glossy ganoderma of the present invention all need be obtained the raw material that contains the ganoderma active material, can be any of Ganoderma powder, Ganoderma water extract, Ganoderma fermentation liquid.Its characteristics are:
1. by weight/and volume ratio preparation red koji fermentation jar culture medium, its composition has: the ganoderma active raw material, Chile saltpeter 0.1-0.5%, potassium dihydrogen phosphate 0.1-0.25%, seven water magnesium phosphate 0.1-0.25%, all the other volumes are supplied with water; After sterilizing, insert the Monascus anka Nakazawa et sato seed, cultivated 5-8 days for 26-27 ℃, when pH value 7-8, stop fermentation, obtain liquid and solid product behind the filtering fermentation liquor respectively, prepare to be used for preparation.Wherein, can to adopt Ganoderma powder be that 4-6%, Ganoderma water extract are that 80-90%, Ganoderma fermentation liquid are any form of 80-90% to the weight of ganoderma active raw material.
2. by weight/and volume ratio preparation red koji fermentation jar culture medium, its composition has: rice meal 1-5%, Chile saltpeter 0.3-0.5%, potassium dihydrogen phosphate 0.2-0.35%, seven water magnesium phosphate 0.2-0.3%, all the other volumes are supplied with water; After sterilizing, insert the Monascus anka Nakazawa et sato seed, cultivated 5-8 days, and obtained Monas cuspurpureus Went fermentation liquid for 26-27 ℃; Mixed with Ganoderma water extract or Ganoderma fermentation liquid by 1: 1, stir, obtain liquid and solid product after the filtration respectively, prepare to be used for preparation.
Obtain containing the liquid and the solid product of active components of glossy ganoderma red koji fermentation thing by said method of the present invention, can prepare following any monascus preparation:
A, press 0.1-0.25mg/g add acesulfame potassium in fluid product, the packing sterilization obtains the Monas cuspurpureus Went oral liquid, main functional component content: crude polysaccharides 〉=5mg/100g, total flavones 〉=4mg/100g, lovastatin 〉=0.15mg/100g;
B, with the fluid product vacuum concentration, be encapsulated in after the sterilization in the soft capsule, obtain the monascus soft capsule agent, main functional component content: crude polysaccharides 〉=9mg/100g, total flavones 〉=7mg/100g, lovastatin 〉=0.25mg/100g;
C, with the solid product drying and crushing, cross the 80-100 mesh sieve, undersized powder packing obtains Hongqu powder (red colouring agent) (loosing) agent, main functional component content: crude polysaccharides 〉=8mg/100g, total flavones 〉=6mg/100g, lovastatin 〉=0.2mg/100g;
D, the solid product drying and crushing is sieved, powder is sub-packed in the capsule, obtains the Monas cuspurpureus Went capsule, main functional component content: crude polysaccharides 〉=8mg/100g, total flavones 〉=6mg/100g, lovastatin 〉=0.2mg/100g;
E, the solid product drying and crushing is sieved, in powder, add starch 1-3%, compacting Monas cuspurpureus Went tablet, main functional component content: crude polysaccharides 〉=7mg/100g, total flavones 〉=5mg/100g, lovastatin 〉=0.15mg/100g;
F, the solid product drying and crushing is sieved, in powder, add starch 2-3% and Mel, make the Monas cuspurpureus Went honey pill agent, main functional component content: crude polysaccharides 〉=5mg/100g, total flavones 〉=4mg/100g, lovastatin 〉=0.13mg/100g;
G, the Mel low baking temperature is boiled to wax yellow, add the solid product powder by 1: 1 weight and stir evenly and make the Monas cuspurpureus Went unguentum, main functional component content: crude polysaccharides 〉=4mg/100g, total flavones 〉=3mg/100g, lovastatin 〉=0.1mg/100g;
H, with fluid product packing sterilization, obtain the liquid food additive, main functional component content: crude polysaccharides 〉=4mg/100g, total flavones 〉=3mg/100g, lovastatin 〉=0.1mg/100g.
The monascus preparation that the present invention is prepared, except that being used for health food, food additive, further purification, determine all the components and content after, can develop and be used for medicine.
The applicant is that raw material carries out " Ganoderma is red " oral liquid formulations that purplish red koji fermentation obtains with the Ganoderma fermentation liquid as stated above, has blood fat reducing and hepatoprotective function through the examination clothes.Functional component content is after testing:
Total flavones: 〉=9mg/100g, the auxiliary adjustment of blood fat function;
Lovastatin (Lovastatin): 〉=0.3mg/100g, the auxiliary adjustment of blood fat function;
Unsaturated fatty acid: 〉=30mg/100g, the auxiliary adjustment of blood fat function;
Crude polysaccharides: 〉=10mg/100g has assistant protection function to chemical liver injury.
Zoopery is the result show: ' Ganoderma is red ' continuously per os gave animal after 30 days, can reduce significantly that the content of glutamate pyruvate transaminase reaches 35% in the rat blood serum; Can significantly reduce serum total cholesterol, triglyceride.The human experiment experimental result shows: ' Ganoderma is red ' falls that the T-CHOL effective percentage is 83.9%, the triglyceride reducing effective percentage is 85.7%, the blood fat reducing effective percentage is 75.0%, and experimenter's serum total cholesterol, triglyceride obviously reduce.And contrast and experiment shows: single Ganoderma preparation reduces the content of glutamate pyruvate transaminase in the rat blood serum at 10-30%, and single monascus preparation reduces human body triglyceride effective percentage at 30-80%.
The monascus preparation that contains active components of glossy ganoderma that the present invention utilizes modern biotechnology to make, technology advanced person, simple possible not only have the several physiological active substances of Ganoderma, Monas cuspurpureus Went product, more produce some other nutrients and materials; Through Preliminary detection, be rich in a large amount of polysaccharide, flavone, lovastatin, unsaturated fatty acid, protein, aminoacid, r-aminobutyric acid, trace element etc., more single Ganoderma of effect or Monas cuspurpureus Went are better.
Modern medicine study proves that many materials comprise that lipid and lipoprotein etc. are to process, produce at liver and decomposition, excretory.In case liver is ill, then lipid and lipoprotein also will get muddled.The present invention has the functions such as hepatoprotective of functions such as the blood fat reducing of Monas cuspurpureus Went and Ganoderma concurrently, with both organically combinations, its function is complemented each other, and the product novelty is different from traditional Monas cuspurpureus Went or Ganoderma, has more market potential.At present China has entered aging society, and the aged has reached 12%, people with hyperlipidemia and be the trend that increases year by year, and especially to some slight hyperlipemic patients, the present invention has huge market.
The specific embodiment
The acquisition methods that contains the ganoderma active material has three kinds:
A, Ganoderma powder: Ganoderma sporophore is thinly sliced drying and crushing powdering, polyoses content 0.2%.
B, Ganoderma water extract: the 100g Ganoderma sporophore is ground into the Semen phaseoli radiati size, soaks with 80 ℃ in 1 premium on currency and filters in 1 hour, is the extracting solution first time; Add 1 liter in water in residue again, 80 ℃ were soaked 3 hours, and twice extracting solution is merged, and obtained Ganoderma water extract.
C, Ganoderma fermentation liquid: preparation fermentation tank culture medium (each components by weight: sucrose 4%, glucose 2%, potassium dihydrogen phosphate 0.1%, magnesium sulfate 0.1%, yeast powder 0.4%, all the other volumes add water and supply), after sterilizing, insert the Ganderma lucidum seed, fermentation tank was cultivated 4 days for 27 ℃, stopped fermentation during pH3-4, obtained Ganoderma fermentation liquid.
Purplish red aspergillosis kind used in the following example is purchased the institute of microbiology in the Chinese Academy of Sciences, obtains liquid seeds after amplification culture.The combination of each raw material and each method and be not limited to this in following examples.
Embodiment 1: preparation Monas cuspurpureus Went oral liquid
The preparation fermentation tank culture medium (by 1 liter of proportioning: rice meal 20g, Chile saltpeter 5g, potassium dihydrogen phosphate 2g, seven water magnesium phosphate 2g, all the other volumes add water and supply) sterilization; Purplish red alcoholic fermented product starter is inserted fermentation tank, cultivated 5 days, and obtained Monas cuspurpureus Went fermentation liquid for 27 ℃.Ganoderma fermentation liquid is added by 1: 1 volume, stir, filter and obtain filtrate and solids.Press 0.25mg/g in the filtrate and add acesulfame potassium, the packing sterilization obtains the Monas cuspurpureus Went oral liquid, main functional component content: crude polysaccharides 5mg/100g, total flavones 4.5mg/100g, lovastatin 0.16mg/100g.
Embodiment 2: preparation Monas cuspurpureus Went oral liquid
The preparation fermentation tank culture medium (by 1 liter of proportioning: Ganoderma fermentation liquid 800g, Chile saltpeter 4g, potassium dihydrogen phosphate 1g, seven water magnesium phosphate 2g, all the other volumes add water and supply) sterilization; Purplish red alcoholic fermented product starter is inserted fermentation tank, cultivated 7 days for 26 ℃.Filtering fermentation liquor obtains filtrate and solids.Press 0.1mg/g in the filtrate and add acesulfame potassium, the packing sterilization obtains the Monas cuspurpureus Went oral liquid, main functional component content: crude polysaccharides 10mg/100g, total flavones 9mg/100g, lovastatin 0.30mg/100g.
Embodiment 3: preparation Monas cuspurpureus Went oral liquid
The preparation fermentation tank culture medium (by 1 liter of proportioning: Ganoderma powder 50g, Chile saltpeter 3.5g, potassium dihydrogen phosphate 2g, seven water magnesium phosphate 1.5g, all the other volumes add water and supply) sterilization; Purplish red alcoholic fermented product starter is inserted fermentation tank, cultivated 6 days for 27 ℃.Filtering fermentation liquor obtains filtrate and solids.Press 0.2mg/g in the filtrate and add acesulfame potassium, the packing sterilization obtains the Monas cuspurpureus Went oral liquid, main functional component content: crude polysaccharides 6.5mg/100g, total flavones 5.4mg/100g, lovastatin 0.17mg/100g.
Embodiment 4: the agent of preparation monascus soft capsule
The preparation fermentation tank culture medium (by 1 liter of proportioning: rice meal 30g, Chile saltpeter 4g, potassium dihydrogen phosphate 2g, seven water magnesium phosphate 2.5g, all the other volumes add water and supply) sterilization; Purplish red alcoholic fermented product starter is inserted fermentation tank, cultivated 5 days, and obtained Monas cuspurpureus Went fermentation liquid for 27 ℃.Added Ganoderma water extract by 1: 1, stir, filter and obtain filtrate and solids.One times of filtrate vacuum concentration is encapsulated in after the sterilization in the soft capsule, obtains the monascus soft capsule agent, main functional component content: crude polysaccharides 9.5mg/100g, total flavones 7mg/100g, lovastatin 0.25mg/100g.
Embodiment 5: preparation Hongqu powder (red colouring agent) (loosing)
The solids that embodiment 1,2,3,4 is obtained mixes, and places 60 ℃ of oven dry of calorstat, pulverizes the 80-100 mesh sieve, undersized powder packing, obtain Hongqu powder (red colouring agent) (loosing) agent, main functional component content: crude polysaccharides 8.5mg/100g, total flavones 6mg/100g, lovastatin 0.21mg/100g.
This powder can be used as the food additive (addition 0.1-0.5%) of solid food (as bread, cookies etc.).
Embodiment 6: preparation Monas cuspurpureus Went capsule
The powder that embodiment 5 is obtained is sub-packed in the capsule, obtains the Monas cuspurpureus Went capsule, main functional component content: crude polysaccharides 8.5mg/100g, total flavones 6mg/100g, lovastatin 0.21mg/100g.
Embodiment 7: preparation Monas cuspurpureus Went tablet
Add 3% starch in the powder that embodiment 5 is obtained, compacting Monas cuspurpureus Went tablet, main functional component content: crude polysaccharides 8.0mg/100g, total flavones 5.8mg/100g, lovastatin 0.2mg/100g.
Embodiment 8: preparation Monas cuspurpureus Went honey pill agent
The fine powder that embodiment 5 is obtained adds 3% starch, makes the Monas cuspurpureus Went honey pill agent with Mel, main functional component content: crude polysaccharides 5.0mg/100g, total flavones 4.0mg/100g, lovastatin 0.13mg/100g.
Embodiment 9: preparation Monas cuspurpureus Went unguentum
The Mel low baking temperature is boiled to wax yellow, and the powder that adding example 5 obtains stirs evenly at 1: 1, makes the Monas cuspurpureus Went unguentum, main functional component content: crude polysaccharides 4mg/100g, total flavones 3mg/100g, lovastatin 0.11mg/100g.
Embodiment 10: get in the example 31 liter of fermentation liquid, obtain lyophilized powder through the vacuum concentration postlyophilization, add excipient more after crushed and make tablet, the preparation that can to obtain main functional component content crude polysaccharides be 2mg/g, total flavones 1.8mg/g, lovastatin 0.06mg/g.This example is to want that the method that the application is described can prepare the higher preparation of content.
The filtrate that embodiment 1-4 obtains all can be as food additive, and it has the function of health product, has the effect of coloring agent again.As adding in fruit jelly or the beverage by 0.1-0.5%.
The main functional component of product of the present invention is behind purification, it is higher that its content can reach, and it can be very high (as lovastatin 80mg/ time) as the survival dose of single component, but because the main effect of product of the present invention is by the various ingredients results of interaction, and country has only the minimum flow requirement to the main functional component content of health product, so among the application the upper limit of main functional component content limit with survival dose obviously improper, so the application only defines minimum content.
Claims (10)
1, a kind of preparation method that contains the monascus preparation of active components of glossy ganoderma, it is characterized in that, by weight/and volume ratio preparation red koji fermentation jar culture medium, its composition has: ganoderma active raw material, Chile saltpeter 0.1-0.5%, potassium dihydrogen phosphate 0.1-0.25%, seven water magnesium phosphate 0.1-0.25%, all the other volumes replenish with water; After sterilizing, insert the Monascus anka Nakazawa et sato seed, cultivated 5-8 days for 26-27 ℃, when pH value 7-8, stop fermentation, obtain liquid and solid product behind the filtering fermentation liquor respectively; Any form of the Ganoderma fermentation liquid of the Ganoderma powder that described ganoderma active raw material employing weight is 4-6% or the Ganoderma water extract of 80-90% or 80-90%.
2, preparation method according to claim 1 is characterized in that, described Monas cuspurpureus Went strain is purplish red aspergillosis kind.
3, preparation method according to claim 1, it is characterized in that, the method that resulting fluid product is prepared the Monas cuspurpureus Went oral liquid is: press 0.1-0.25mg/g and add acesulfame potassium in fluid product, the packing sterilization, obtain the Monas cuspurpureus Went oral liquid, main functional component content: crude polysaccharides 〉=5mg/100g, total flavones 〉=4mg/100g, lovastatin 〉=0.15mg/100g.
4, preparation method according to claim 1, it is characterized in that, the method that resulting fluid product is prepared monascus soft capsule is: with the fluid product vacuum concentration, be encapsulated in the soft capsule after the sterilization, obtain the monascus soft capsule agent, main functional component content: crude polysaccharides 〉=9mg/100g, total flavones 〉=7mg/100g, lovastatin 〉=0.25mg/100g.
5, preparation method according to claim 1, it is characterized in that, the method that resulting fluid product is prepared food additive is: the fluid product packing is sterilized, obtain food additive, main functional component content: crude polysaccharides 〉=4mg/100g, total flavones 〉=3mg/100g, lovastatin 〉=0.1mg/100g.
6, preparation method according to claim 1, it is characterized in that, the method that resulting solid product is prepared the Monas cuspurpureus Went powder is: with the solid product drying and crushing, cross the 80-100 mesh sieve, undersized powder packing, obtain the Monas cuspurpureus Went powder, main functional component content: crude polysaccharides 〉=8mg/100g, total flavones 〉=6mg/100g, lovastatin 〉=0.2mg/100g.
7, preparation method according to claim 1, it is characterized in that, the method that resulting solid product is prepared the Hongqu powder (red colouring agent) agent capsules is: the solid product drying and crushing is sieved, powder is sub-packed in the capsule, obtain the Hongqu powder (red colouring agent) agent capsules, main functional component content: crude polysaccharides 〉=8mg/100g, total flavones 〉=6mg/100g, lovastatin 〉=0.2mg/100g.
8, preparation method according to claim 1, it is characterized in that, the method that resulting solid product is prepared the Monas cuspurpureus Went tablet is: the solid product drying and crushing is sieved, in powder, add starch 1-3%, compacting Monas cuspurpureus Went tablet, main functional component content: crude polysaccharides 〉=7mg/100g, total flavones 〉=5mg/100g, lovastatin 〉=0.15mg/100g.
9, preparation method according to claim 1, it is characterized in that, the method that resulting solid product is prepared the Monas cuspurpureus Went honey pill agent is: the solid product drying and crushing is sieved, in powder, add starch 2-3% and Mel, make the Monas cuspurpureus Went honey pill agent, main functional component content: crude polysaccharides 〉=5mg/100g, total flavones 〉=4mg/100g, lovastatin 〉=0.13mg/100g.
10, preparation method according to claim 1, it is characterized in that, the method that resulting solid product is prepared the Monas cuspurpureus Went unguentum is: the Mel low baking temperature is boiled to wax yellow, adding the solid product powder by 1: 1 weight stirs evenly and makes the Monas cuspurpureus Went unguentum, main functional component content: crude polysaccharides 〉=4mg/100g, total flavones 〉=3mg/100g, lovastatin 〉=0.1mg/100g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100790919A CN100528177C (en) | 2003-11-19 | 2004-09-30 | Red yeast preparation containing active components of glossy ganoderma and its preparation process |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2003101059377A CN1543876A (en) | 2003-11-19 | 2003-11-19 | Novel monascin oral liquid and method for producing the same |
| CN200310105937.7 | 2003-11-19 | ||
| CNB2004100790919A CN100528177C (en) | 2003-11-19 | 2004-09-30 | Red yeast preparation containing active components of glossy ganoderma and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1636588A CN1636588A (en) | 2005-07-13 |
| CN100528177C true CN100528177C (en) | 2009-08-19 |
Family
ID=34862465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100790919A Expired - Fee Related CN100528177C (en) | 2003-11-19 | 2004-09-30 | Red yeast preparation containing active components of glossy ganoderma and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100528177C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055461A (en) * | 2015-07-23 | 2015-11-18 | 广西仙草堂制药有限责任公司 | Lipid-lowering Ganoderma health product and its preparation method |
| CN113332389A (en) * | 2021-07-09 | 2021-09-03 | 杭州雪域生物技术有限公司 | Red yeast rice and lucid ganoderma composition as well as preparation method and application thereof |
-
2004
- 2004-09-30 CN CNB2004100790919A patent/CN100528177C/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 血脂康有效成分的研究. 张茂良等.中国新药杂志，第7卷第3期. 1998 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1636588A (en) | 2005-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102242070A (en) | Method for artificially culturing paecilomyces cicadae and application of culturing product thereof | |
| CN103740566B (en) | Rosa roxbunghii medicinal liquor and preparation method thereof | |
| CN108904563B (en) | Processing method and application of whole-plant ginseng raw stock | |
| CN104087488A (en) | Raspberry compound fruit wine and brewing method thereof | |
| CN106350458A (en) | Method for improving yield and activity of fermentation products of agaricus blazei murill liquid | |
| CN109480281A (en) | A kind of organic black fruit fructus lycii ferment and preparation method thereof | |
| CN106954843A (en) | A kind of composite plant enzyme stoste, feature composite plant enzyme stoste and preparation method thereof and functional food | |
| CN103191332A (en) | Composition and health-care product with stomach-invigorating and digestion-promoting functions | |
| CN106244372A (en) | A kind of ferment Rhizoma Gastrodiae health-preserving beverage improving sleep and preparation technology and application | |
| CN108477565A (en) | A kind of lucid ganoderma cream is grown and preparation method thereof | |
| CN101155521A (en) | Novel method for preparing ginseng to obtain increased amount of ginsenoside rg5 | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN109528814A (en) | A kind of probiotics and its preparation method and application of lactobacillus-fermented Radix Astragali | |
| KR101062172B1 (en) | Anti-cancer health food containing mushroom fermented ginseng powder | |
| CN104906361A (en) | Hypolipidemic yellow rice wine and making method thereof | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| CN106343567A (en) | Noni oral liquid and preparing method thereof | |
| CN104928140A (en) | Compound fermentation type winter-jujube health care wine and production technology thereof | |
| CN110777042A (en) | SOD (superoxide dismutase) white spirit with liver nourishing and health care effects and preparation method and packaging structure thereof | |
| CN110200182A (en) | A kind of plant fermentation beverage and preparation method thereof having hearing-improing and eyesight improving function | |
| CN109527547A (en) | A kind of preparation method of lactobacillus-fermented mulberries polyoses oral liquid | |
| CN109805235A (en) | A kind of drop four high wheat perfume (or spice) complex polypeptide solid beverages, Preparation method and use | |
| CN100528177C (en) | Red yeast preparation containing active components of glossy ganoderma and its preparation process | |
| CN103725574A (en) | Method for preparing rosa laevigata and wolfberry fruit wine as well as health-care functions and application of rosa laevigata and wolfberry fruit wine | |
| CN107279983A (en) | The preparation method of paper mulberry tree cordyceps sinensis albumen peptide nutrient powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Red yeast prepn containing active components of glossy ganoderma and its prepn process Effective date of registration: 20150929 Granted publication date: 20090819 Pledgee: Shaanxi Qin Nong rural commercial bank Limited by Share Ltd. Pledgor: XI'AN LIJUN PHARMACEUTICAL Co.,Ltd. Registration number: 2015990000836 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200710 Granted publication date: 20090819 Pledgee: Shaanxi Qin Nong rural commercial bank Limited by Share Ltd. Pledgor: Xi'an Lijun Pharmaceutical Co.,Ltd. Registration number: 2015990000836 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Ji Wei Document name: Notice of Termination of Patent Rights |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090819 |